title: ACR Appropriateness Criteria® postoperative adjuvant therapy in non-small cell lung cancer.
abstract: Therapeutic options for postoperative adjuvant treatment for patients with non-small cell lung cancer (NSCLC) continue to evolve, and may include postoperative radiotherapy (PORT) and chemotherapy, alone or in combination. The use of platinum-based adjuvant chemotherapy has been demonstrated to confer an improvement in overall survival in patients with completely resected, stage N1 or N2 NSCLC, in several randomized trials and 2 meta-analyses. Consideration may also be given to adjuvant chemotherapy in patients with node-negative NSCLC, when the primary tumor is >4 cm, based on subset analyses of recent prospective studies. The precise role of PORT is less well defined. Older randomized studies indicated that the toxicity of PORT outweighed the potential improvement in local control, but studies using more modern radiation techniques show significantly reduced toxicity, inferring that select patients may benefit. Relative indications for PORT include the presence of mediastinal lymph nodes, positive surgical margins, and considerations with regard to the extent and type of resection. This study by the lung cancer expert panel of the American College of Radiology summarizes the recent evidence-based literature that addresses the use of postoperative adjuvant radiotherapy and chemotherapy in patients with NSCLC, illustrated with clinical scenarios. The sequencing of radiotherapy and chemotherapy is discussed, along with issues regarding radiotherapy dose and fractionation, and the appropriate use of intensity modulated radiation therapy and particle therapy.
authors.affiliation: Yale University School of Medicine, New Haven, CT, USA. roy.decker@yale.edu
authors.forename: Roy H
authors.initials: RH
authors.lastname: Decker
authors.forename: Corey J
authors.initials: CJ
authors.lastname: Langer
authors.forename: Kenneth E
authors.initials: KE
authors.lastname: Rosenzweig
authors.forename: Joe Yujiao
authors.initials: JY
authors.lastname: Chang
authors.forename: Richard M
authors.initials: RM
authors.lastname: Gewanter
authors.forename: Mark E
authors.initials: ME
authors.lastname: Ginsburg
authors.forename: Feng-Ming
authors.initials: FM
authors.lastname: Kong
authors.forename: Brian E
authors.initials: BE
authors.lastname: Lally
authors.forename: Gregory M
authors.initials: GM
authors.lastname: Videtic
authors.forename: Benjamin
authors.initials: B
authors.lastname: Movsas
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000532:radiotherapy* / Q000601:surgery; D017024:Chemotherapy, Adjuvant / Q000592:standards*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy* / Q000601:surgery; D011184:Postoperative Period; D018714:Radiotherapy, Adjuvant / Q000592:standards*